[
  {
    "criterion": "Provides a clear and concise comparison of dupilumab, omalizumab, and mepolizumab for chronic rhinosinusitis with nasal polyps.",
    "axis": "completeness",
    "point": 8
  },
  {
    "criterion": "States that dupilumab, omalizumab, and mepolizumab have inconsistent endoscopic polyp size reduction in RCT data.",
    "axis": "accuracy",
    "point": -5
  },
  {
    "criterion": "Asks the user to clarify their request for a comparison of the three biologics.",
    "axis": "context_awareness",
    "point": 5
  },
  {
    "criterion": "Uses technical jargon or complex medical terms that might be difficult for a non-expert to understand.",
    "axis": "communication_quality",
    "point": -8
  },
  {
    "criterion": "Incorrectly states that dupilumab, omalizumab, and mepolizumab have the same mechanism of action.",
    "axis": "accuracy",
    "point": -9
  },
  {
    "criterion": "Fails to mention the importance of patient-reported outcomes, such as SNOT-22, in the comparison of the three biologics.",
    "axis": "completeness",
    "point": -7
  },
  {
    "criterion": "Correctly highlights the steroid-sparing benefits of dupilumab, omalizumab, and mepolizumab.",
    "axis": "accuracy",
    "point": 6
  },
  {
    "criterion": "Incorrectly claims that step therapy is not required for dupilumab, omalizumab, and mepolizumab.",
    "axis": "accuracy",
    "point": -8
  },
  {
    "criterion": "Provides a detailed explanation of the RCT evidence supporting the use of dupilumab, omalizumab, and mepolizumab for chronic rhinosinusitis with nasal polyps.",
    "axis": "completeness",
    "point": 9
  },
  {
    "criterion": "Fails to mention potential adverse events, such as injection site reactions or rare systemic issues, associated with dupilumab, omalizumab, and mepolizumab.",
    "axis": "completeness",
    "point": -6
  },
  {
    "criterion": "Correctly concludes that the RCT evidence generally supports the use of dupilumab, omalizumab, and mepolizumab for chronic rhinosinusitis with nasal polyps.",
    "axis": "completeness",
    "point": 8
  },
  {
    "criterion": "Incorrectly states that dupilumab, omalizumab, and mepolizumab are not effective in reducing nasal symptoms, polyp size, and quality of life.",
    "axis": "accuracy",
    "point": -10
  }
]